Rheumatology
From the Journals
Arthritis treatment costs per person held steady from 2008 to 2014
But why did it cost $60 billion more in aggregate treatment costs in 2014?
From the Journals
Predictors may help to spot risk for hydroxychloroquine nonadherence
A detailed look at the trajectories of patients who stop, continue, or never start the drug.
From the Journals
DMARDs may hamper pneumococcal vaccine response in systemic sclerosis patients
Vaccination before DMARD initiation or while on a drug holiday might be a good idea.
From the Journals
Putting a number on biologic DMARD costs
Burden of rheumatoid arthritis “may become outsized” as more patients use biologic disease-modifying antirheumatic drugs.
Conference Coverage
Contraceptive use appears low in teen girls on teratogenic medications
SAN DIEGO – Study finds 7.6% became pregnant over a 3-year period, and only 25% of those had filled birth control prescriptions.
From the Journals
Chikungunya virus goes undetected despite chronic arthritis in 25% of patients after 20 months
The potential mechanisms by which chikungunya may cause chronic arthritis after viral clearing remain unknown.
From the Journals
Children of moms with RA have higher risk of RA, too
These children also had a higher risk of thyroid disease and epilepsy.
News
FDA approves tofacitinib for psoriatic arthritis
The drug is now the only Janus kinase inhibitor approved to treat psoriatic arthritis.
News
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
It is the third biosimilar of Remicade to be approved by the FDA.
Conference Coverage
Sprifermin shows cartilage-building potential in knee OA patients
Interim results indicate that sprifermin could be the first investigational medicinal product to show a dose-dependent increase in cartilage...
News
FDA approves first therapy treatment for EGPA
Approval of using mepolizumab for EGPA was based on data from a 52-week clinical trial that compared it with placebo, according to the FDA.